Skip to main content

Topic

Pharmacovigilance

32 published works

  1. As Prescribed

    Adverse Events Centralized: What the Launch of FDA’s New Adverse Event Monitoring System Means for Companies

    By Morgan Lewis

    FDA announced on March 11, 2026 the launch of the Adverse Event Monitoring System (AEMS) , a modernized database designed to centralize and streamline the analysis and publication of adverse…

  2. Drug Injury Watch

    Ozempic Tablets and Rybelsus Pancreatitis Side Effects Warnings 2026 Update

    By Tom Lamb

    Acute Pancreatitis, Including Fatal Hemorrhagic And Necrotizing Pancreatitis – Death Cases (Posted by Tom Lamb at Drug Injury Watch) In October 2025, Rybelsus pancreatitis side effects warnings were added to the Rybelsus “drug…

  3. GoodLifeSci

    Key Steps Toward Using Artificial Intelligence in Pharmacovigilance – Sidley Insights on the Recent CIOMS Draft Report

    By Torrey Cope, Anna-Shari Melin, Andrew James

    The Council for International Organizations of Medical Sciences Working Group XIV (CIOMS) has produced a draft report (the Draft Report) on the use of artificial intelligence (AI) in pharmacovigilance (PV).…

  4. BioSlice Blog

    Updates to the EU Pharmacovigilance Rules: Key Takeaways for Marketing Authorisation Holders

    By Alexander Roussanov, Heba Jalil

    On 22 July 2025, the European Commission adopted Implementing Regulation (EU) 2025/1466 (“Regulation”), updating the EU pharmacovigilance (or “PV”) rules by way of amendments to Implementing Regulation (EU) No 520/2012.…

  5. Inside EU Life Sciences

    European Commission Consults on Update to Pharmacovigilance Rules

    By Grant Castle, Dan Spivey

    On 18 December 2024, the European Commission published a proposed implementing regulation relating to pharmacovigilance (“PV”) requirements for human medicines marketed in the EU (“Proposal”), which will update European Commission…

  6. Drug Injury Watch

    Syfovre Safety-Benefit Assessment by Europe’s Drug Regulator Differs From FDA

    By Tom Lamb

    EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing "significant risk of adverse events"   (Posted by Tom Lamb at Drug Injury Watch)   There seems to be some disagreement about…

  7. Inside EU Life Sciences

    EU Pharma Revision Series: Pharmacovigilance

    By Grant Castle, Marie Doyle-Rossi, Anna Wawrzyniak, Valeria Sturla

    The European Commission’s proposal to amend the current pharmaceutical regulatory framework includes a draft Directive on medicines for human use (the “Proposed Directive”) and a draft Regulation on the central…

  8. Drug & Device Law

    When the Law Isn’t Really the Law – Creative Jurisprudence in Mostly Bad C.D. California Singulair Decision

    By Rachel B. Weil

    We have decided that 2023 will be a year of new adventures for us.  We are dipping our toes into the world of dog shows (our gorgeous poodle puppy is…

  9. Global Policy Watch

    The Spanish AEPD Publishes Statement on the Interplay Between its Code of Conduct for the Pharmaceutical Industry and the Potential EU Code of Conduct on Clinical Trials

    By Kristof Van Quathem, Anna Sophia Oberschelp de Meneses

    On December 28, 2022, the Spanish Data Protection Authority (“AEPD”) published a statement on the interplay between its recently approved Spanish code of conduct for the pharmaceutical industry and the European Federation of Pharmaceutical…

  10. Inside Privacy

    The Spanish AEPD Publishes Statement on the Interplay Between its Code of Conduct for the Pharmaceutical Industry and the Potential EU Code of Conduct on Clinical Trials

    By Kristof Van Quathem, Anna Sophia Oberschelp de Meneses

    On December 28, 2022, the Spanish Data Protection Authority (“AEPD”) published a statement on the interplay between its recently approved Spanish code of conduct for the pharmaceutical industry and the…